ASCO 2017 - Domenica Lorusso Interview Part 2

Dr Domenica Lorusso discusses the ICON 6 trial and the difficulties in analyzing survival benefits in ovarian cancer patients. She also discusses the ANTHALYA study and toxicity of bevacizumab.

ASCO 2017 - Domenica Lorusso Interview Part 2

ASCO 2017 - Domenica Lorusso Interview Part 1

ASCO 2017 - Domenica Lorusso Interview Part 3

ASCO 2017: the Italian Insight from Chicago

Overcoming resistance to PARPi in ovarian cancer

What are the benefits of including chemotherapy in the treatment of endometrial cancer?

Should all platinum sensitive patients recieve PARP inhibitors?

ASCO 2017: overview sui tumori ginecologici

ESMO’s scientific value for gynecologic oncology

Lymphadenectomy and Survival in Ovarian Cancer

Unmet clinical needs for platinum-resistant ovarian cancer patients

PARP inhibitor rechallenging in ovarian cancer

ASCO 2013: il punto sui tumori ginecologici - Lorusso

Tumore ovarico, le ricerche dell'Istituto Nazionale Tumori

Brian Slomovitz, MD, on incorporating biomarker-driven therapy in ovarian cancer

Sapere se si è a rischio per tumore

Prevenzione primaria con test BRCA per tumore ovarico, i dati dallo studio Venus